Profile data is unavailable for this security.
About the company
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
- Revenue in CHF (TTM)524.89m
- Net income in CHF166.10m
- Incorporated1993
- Employees86.00
- LocationBB Biotech AGSchwertstrasse 6SCHAFFHAUSEN 8200SwitzerlandCHE
- Phone+41 526240845
- Fax+41 442676701
- Websitehttps://www.bbbiotech.ch/
Profile
| Management group(s) | Bellevue Asset Management, LLC |
|---|---|
| AIC sector | -- |
| ISIN | CH0038389992 |
| Launch date | 09 Nov 1993 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | CHF |
Objective
BB Biotech invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. It focuses on biotech companies whose products address areas of significant unmet medical needs and that are generating above-average sales and profit growth. BB Biotech’s investment portfolio will usually consist of 20 to 35 biotechnology companies. This will include 5 to 8 large core positions, which together will account for up to 2/3 of the portfolio.New investments in mid-cap companies will have a weighting of between 1% and a maximum of 5% to ensure that both upside potential and R&D risks are adequately addressed.Non-listed companies should not exceed 10% of the portfolio.
Managed by
| Not Disclosed |
|---|
Management & contract fees
The Company pays a 1.1% all-in fee without any additional fixed or performance-based elements of compensation for the asset management company.
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galapagos NV | 261.41m | -404.40m | 1.70bn | 558.00 | -- | 0.7637 | -- | 6.51 | -6.74 | -6.62 | 4.35 | 37.13 | 0.0747 | 1.02 | 6.32 | 407,558.30 | -11.55 | -2.04 | -12.74 | -2.28 | 84.31 | -- | -154.70 | -27.56 | 8.56 | -- | 0.0031 | -- | 14.99 | -20.82 | 67.85 | -- | 12.44 | -- |
| BioArctic AB | 164.87m | 86.01m | 2.06bn | 122.00 | 28.51 | 14.50 | 22.98 | 12.48 | 11.30 | 11.30 | 21.64 | 22.22 | 1.04 | -- | -- | 17,909,460.00 | 54.12 | -2.87 | 67.19 | -3.22 | 97.08 | 86.59 | 52.17 | -12.41 | -- | -- | 0.0231 | -- | -58.22 | -1.80 | -177.24 | -- | 52.19 | -- |
| Genus plc | 704.96m | 20.22m | 2.11bn | 3.17k | 105.43 | 4.20 | 31.11 | 3.00 | 0.2874 | 0.2874 | 10.07 | 7.21 | 0.7132 | -- | 6.12 | 212,239.80 | 2.05 | 2.91 | 2.40 | 3.43 | -- | -- | 2.87 | 4.28 | 1.32 | 7.89 | 0.3584 | 70.94 | 0.5981 | 4.06 | 144.30 | -11.37 | -8.94 | 1.92 |
| BB BIOTECH AG | 524.89m | 166.10m | 2.55bn | 86.00 | 15.23 | 1.10 | -- | 4.85 | 3.02 | 3.02 | 9.58 | 41.83 | 0.2179 | -- | -- | 6,103,396.00 | 6.90 | -1.24 | 7.32 | -1.35 | 99.84 | 97.19 | 31.65 | -39.47 | -- | 1.50 | 0.00 | -- | 21,076.79 | -31.20 | 136.74 | -35.45 | -- | -11.94 |
| Zealand Pharma A/S | 1.12bn | 798.02m | 3.49bn | 440.00 | 4.39 | 1.85 | 4.35 | 3.12 | 91.00 | 91.00 | 129.24 | 215.72 | 0.6929 | 3.05 | 75.81 | 27,328,360.00 | 49.52 | -32.33 | 52.34 | -36.49 | 99.99 | 95.31 | 71.47 | -515.03 | 14.10 | -- | 0.0261 | -- | -81.71 | 8.69 | -53.30 | -- | -10.98 | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 03 Feb 2026 | 1.96m | 3.54% |
| Saba Capital Management LPas of 26 Aug 2025 | 1.68m | 3.03% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2025 | 1.10m | 1.99% |
| Pictet Asset Management SAas of 31 Oct 2025 | 212.49k | 0.38% |
| Baumann & Cie KmGas of 31 Oct 2025 | 165.00k | 0.30% |
| BlackRock Asset Management Deutschland AGas of 05 Feb 2026 | 163.69k | 0.30% |
| Banque Cantonale Vaudoise (Investment Management)as of 30 Sep 2025 | 144.42k | 0.26% |
| Mirabaud Asset Management (Suisse) SAas of 30 Jun 2025 | 126.00k | 0.23% |
| Union Bancaire Priv�e, UBP SAas of 30 Sep 2025 | 95.76k | 0.17% |
| Hoerner Bank AGas of 30 Jun 2025 | 69.50k | 0.13% |
